Published in Medical Letter on the CDC and FDA, September 25th, 2005
During earlier discussions, the FDA suggested that NeoPharm consider proposing an interim efficacy analysis. The SPA already included two futility analyses and a final efficacy analysis.
An interim efficacy analysis will be conducted by the independent data monitoring committee (DMC), after notification of 160 deaths to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.